# The perspectives of patients with depression toward esketamine, and the influence of their medication adherence on their viewpoints: a Saudi cross-sectional study

**Authors:** Ahmad H. Almadani, Ayedh H. Alghamdi, Fahad B. Alfahad, Abdullah S. Alibrahim, Abdulrahman I. Binbakhit, Ziyad B. Alenazi, Lama M. Alruwaili, Abdulrahman A. Alshahwan, Abdullah K. Muhnna, Mohammed A. Aljaffer

PMC · DOI: 10.3389/fpsyt.2025.1678119 · Frontiers in Psychiatry · 2025-10-29

## TL;DR

This study explores how patients with depression in Saudi Arabia view esketamine treatment and how their medication adherence affects their opinions.

## Contribution

The study provides new insights into patient perspectives on esketamine and the impact of medication adherence in a Saudi Arabian context.

## Key findings

- 52.3% of participants were willing to receive esketamine for depression.
- 77.4% of participants were nonadherent to their current psychiatric medication regimen.
- Cost and medication unavailability were the most common concerns about esketamine.

## Abstract

Nasal esketamine has demonstrated efficacy in the management of treatment-resistant depression and psychiatric emergency due to major depression. This study investigates acceptance and awareness of esketamine as a depression treatment option, focusing on factors that influence patients’ acceptance, including adherence to current medication regimens, regardless of prior esketamine exposure.

This cross-sectional study surveyed 283 adults with depression using a questionnaire and the Medication Adherence Rating Scale (MARS-10).

52.3% of participants were willing to receive esketamine, and 51.2% preferred its weekly or biweekly dosing over daily antidepressants; 79.5% reported cost as a potential barrier. Common concerns included medication unavailability (59.7%), fear of addiction (50.5%), anticipated stigma (24.4%), and first-month dosing frequency (21.2%). Regarding adherence, 77.4% were nonadherent to their current psychiatric medication regimen. Adherence to the current regimen was higher among patients with previous esketamine use (p <.001) and among those who had someone to stay with them during and after treatment (p = .047).

Patients are open to esketamine but have concerns that must be addressed. It also highlights non-adherence as a significant issue in patients with depression. These findings highlight the importance of patients’ education, family involvement, and logistical supports.

## Linked entities

- **Chemicals:** esketamine (PubChem CID 182137)
- **Diseases:** depression (MONDO:0002050)

## Full-text entities

- **Diseases:** depression (MESH:D003866), major depression (MESH:D003865), addiction (MESH:D019966), psychiatric (MESH:D001523)
- **Chemicals:** Nasal esketamine (-), esketamine (MESH:C000629870)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12605915/full.md

## References

63 references — full list in the complete paper: https://tomesphere.com/paper/PMC12605915/full.md

---
Source: https://tomesphere.com/paper/PMC12605915